Bioavailability Study of ACE910

Relative and Absolute Bioavailability Study of ACE910 in Healthy Adult Male Volunteers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222836

Enrollment

Registered

2015-04-28

Start date

2015-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A

Interventions

investigational material(s) Generic name etc : ACE910 INN of investigational material : emicizumab Therapeutic category code : 634 Human blood preparations Dosage and Administration for Investigationa

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Japanese healthy males aged 20-44 years, inclusive

Exclusion criteria

Exclusion criteria: Have thromboembolic disease, such as deep vein thrombosis, or its previous history

Design outcomes

Primary

Measure	Time frame
safety bioavailability pharmacokinetics laboratory tests	—

Secondary

Measure	Time frame
pharmacodynamics Laboratory tests	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026